Opens in a new tab or window About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to ...

for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is indicated for ...

Promising Improvement in Abs-TSS and SVR35 from Phase 1 Trial of Selinexor in Combination with Ruxolitinib Adds Confidence in Phase 3 SENTRY Trial Proactively Increasing Total Sample Size of the ...

"There remains a tremendous unmet need in myelofibrosis, as less than half ... 3 SENTRY trial increases based on the change in the co-primary endpoint to Abs-TSS, the increased sample size and ...

Karyopharm intends to enroll approximately 350 JAKi naïve patients with myelofibrosis in this Phase 3 trial; patients are randomized 2-to-1 to the selinexor arm. The co-primary endpoints will be ...